top of page
Recent Research
CYTK/BMY: aficamten approvable, but may not be better than BMY rival Camzyos
While at first sight, the body of aficamten data in obstructive hypertrophic cardiomyopathy (oHCM) may appear slightly ahead of Camzyos...
Feb 29, 2024
MRK: One big hit amongst smaller approvable assets
MRK: We examine in detail, the prospects of five median term Merck pipeline assets, over the next 6 years and find that there are good...
Feb 5, 2024
MRK: MK-0616: Next gen cholesterol pill?
MRK: Ahead of the first of 3 upcoming 2025 oral PCSK9 CORALreef phase III results in 2Q25, our in-depth analysis suggests a favourable...
Feb 5, 2024
Archive
Search By Tags
Follow Us
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
bottom of page